BioSpace News Archive

This investigation included the association of N-myristoyl transferase (NMT) expression levels with AML patient survival and the in vitro and in vivo demonstration of AML cell killing and tumor reduction with PCLX-001, a proprietary, potent, NMT inhibitor in clinical investigation in Non-Hodgkin’s Lymphoma (NHL) and solid tumor cancer patients.

Caribou Biosciences, Inc. announced the presentation of positive preclinical data for its allogeneic, immune-cloaked, anti-BCMA CAR-T cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), today announced new nonclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) STRO-002, in an e-poster session, at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and collaboration partner Redx Pharma (AIM: REDX) today presented data showing the pan-RAF kinase inhibitor, JZP815, was active in multiple RAF- and RAS-mutant tumor pre-clinical models, with a pharmacokinetic profile that may provide drug exposure required for target engagement in humans.

Omega Therapeutics (NASDAQ: OMGA) (Omega), will present preclinical data highlighting the potential of its lead Omega Epigenomic Controller™, OTX-2002, to regulate overexpression of the c-Myc (MYC) oncogene in models of hepatocellular carcinoma (HCC) in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022,

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive long-term survival data from ReoGlio, an investigator-sponsored phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM).

Tachyon Therapeutics, Inc. (“Tachyon” or “the Company”), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research (“AACR”) Annual Meeting 2022.

Hangzhou Qihan Biotechnology Co., Ltd, an innovative biotechnology company dedicated to applying genome editing technology to cell therapies and organ transplants, today announced preclinical data from its NK cell programs, presented during the poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.

PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced that their recent research will be presented at the 2022 AACR annual meeting, which will be held in New Orleans from April 8 to April 13, 2022.

Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues.